Gameto Highlights Phase III Progress of Fertility Platform and Pipeline Expansion into Menopause

Gameto has shared an update.

The company highlighted a feature interview with CEO and Co-founder Dina Radenkovic Turner in Inside Precision Medicine, where she discussed Gameto’s evolution, its clinical pipeline, and the broader women’s health market. The conversation covered her background, the development of Fertilo—Gameto’s fertility platform now in Phase III clinical trials with more than 100 couples treated and the first babies born outside the U.S.—and Ameno, the company’s next program targeting menopause. Radenkovic Turner also emphasized the underpenetrated nature of women’s health in biopharma, noting the lack of dedicated divisions at major pharmaceutical firms.

For investors, the progress of Fertilo into Phase III with initial real-world outcomes (treated couples and live births) is a key value driver, as it signals advancement toward potential regulatory approval and eventual commercialization in the fertility market. Demonstrated clinical progress and international usage could strengthen Gameto’s position when pursuing additional funding or strategic partnerships. The planned Ameno program suggests a pipeline expansion into menopause, another large and underserved segment that could diversify future revenue streams if clinical development is successful. More broadly, Gameto is positioning itself within a relatively uncrowded biopharma category, which may offer upside if the company can establish clinical credibility and secure reimbursement, though meaningful revenue remains contingent on successful trial outcomes and regulatory milestones.